Research programme: fullerene based antioxidant therapeutics - Tego BioSciences/Merck
Alternative Names: C3Latest Information Update: 24 Mar 2010
At a glance
- Originator Tego BioSciences
- Class Fullerenes; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 11 Jul 2007 Fullerene based antioxidant therapeutics are available for partnering (http://www.tegiobio.com)
- 25 Jun 2007 C Sixty Acquisition Corp is now called Tego BioSciences Corporation
- 26 Mar 2007 C Sixty Inc has been acquired by Arrowhead Research Corporation